EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

Shibue, Tsukasa, Weinberg, Robert A.·2017·Nature Reviews Clinical Oncology
DOI 10.1038/nrclinonc.2017.44

Cites (210)

Items 201–210 of 210

  1. The Role of Myofibroblasts at the Tumor Border of Invasive Colorectal Adenocarcinomas
    Hiroyuki Nakayama, Hideaki Enzan, E Miyazaki, Keiji Naruse, Hiroshi Kiyoku, Makoto Hiroi · 1998 · Japanese Journal of Clinical Oncology
  2. E-cadherin expression: a counterbalance for cancer cell invasion.
    M. Mareel, Kris Vleminckx, Stefan J. T. Vermeulen · 1992 · PubMed
  3. Ras Promotes Transforming Growth Factor-β (TGF-β)-induced Epithelial-Mesenchymal Transition via a Leukotriene B4 Receptor-2-linked Cascade in Mammary Epithelial Cells
    Hyun-Ju Kim, Jung An Choi, Jae‐Hong Kim · 2014 · Journal of Biological Chemistry
  4. Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium
    Friedrich Feuerhake, Winfried Sigg, Eugen Höfter · 1999 · Cell and Tissue Research
  5. Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium
    Friedrich Feuerhake, Winfried Sigg, Eugen Höfter · 2000 · Cell and Tissue Research
  6. Ski and SnoN, potent negative regulators of TGF-β signaling
    Julien, Deheuninck, Kunxin · 2009 · Acta Scientiarum Naturalium Universitatis Sunyatseni
  7. Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse
    Nicolas Boisgerault, Timothy J. Kottke, José S. Pulido et al. · 2013 · Molecular Therapy
  8. Erratum: FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction
    D-W Wu, MC Lee, N-Y Hsu · 2015 · Oncogene
  9. Erratum: FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction
    D-W Wu, MC Lee, N-Y Hsu, T.‐C. Wu, J-Y Wu, YC Wang, Y-W Cheng, C-Y Chen, H Lee · 2017 · Oncogene
  10. A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Lauren A. Byers, David E. Gerber, Julio Antonio Peguero · 2016 · European Journal of Cancer